The Medical Letter on Drugs and Therapeutics
Issue 1480
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI; Drugs for Hypothyroidism; In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma
The full issue is available to subscribers Subscriber Login   
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI

The FDA has approved cangrelor (Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

ANTIPLATELET DRUGS FOR PCI — Current guidelines recommend aspirin plus an oral P2Y12 inhibitor, either clopidogrel (Plavix, and generics), prasugrel (Effient), or ticagrelor (Brilinta), for all patients undergoing PCI.1,2 For prevention of myocardial infarction (MI) and stent thrombosis in patients with acute coronary syndrome, both prasugrel and ticagrelor have been more effective than clopidogrel, but with a higher incidence of bleeding. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1480
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35